Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $50.75 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2024 revenue of $190-210 million, versus the consensus of $197.4 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.